Clinical trials: Primaquine
G6PD Deficiency
Primaquine Enantiomers in G6PD Deficient Human Volunteers
This study is a single center, prospective, cross-over phase 1 trial. Eighteen subjects will be enrolled in the study evaluating the metabolism, pharmacokinetic behavior and tolerability of primaquine enantiomers and placebo over…
- Trial name
- NCT04073953
- Testing
- RPQ, SPQ
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Mississippi, Oxford
Plasmodium Vivax
Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection
This study specifically seeks to provide data on the safety, tolerability and pilot efficacy of short course, high dose primaquine treatment in Papua New Guinean children aged 5-10 years, in a cross-sectional study design.
- Trial name
- NCT02364583
- Testing
- Primaquine
- Where
- Papua New Guinea
- Volunteers
- 150 people
- Sponsor
- Papua New Guinea Institute of Medical Research
Plasmodium Falciparum Malaria
Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar
The general objective of this study is to assess the therapeutic efficacy and safety of artesunate + amodiaquine combined with a single low dose of primaquine (0.25 mg/kg) for the treatment of uncomplicated P.
- Trial name
- AcoV (NCT03773536)
- Testing
- Artesunate-amodiaquine given with single low dose primaquine
- Where
- Tanzania
- Volunteers
- 146 people
- Sponsor
- Professor Anders Björkman
Vivax Malaria
Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)
In Southeast Asia, Plasmodium vivax (Pv) infection reaches 50-80% and bears a greater burden of disease than Plasmodium falciparum (Pf).
- Trial name
- NCT01640574
- Testing
- Dihydroartemisinin-Piperaquine, Chloroquine
- Where
- Thailand
- Volunteers
- 680 people
- Sponsor
- University of Oxford
Malaria,Falciparum
"Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in Bagamoyo District, Tanzania"
This clinical trial evaluates the advantage of prolonging the therapeutic life span of Artemether-lumefantrine from 3 days to 6 days, and addition of single low dose of Primaquine 0.25mg/kg.
- Trial name
- ALU-PQ (NCT03241901)
- Testing
- Artemether-Lumefantrine Tab 20-120mg, Primaquine Phosphate 0.25 mg/kg
- Where
- 2 sites in Tanzania
- Volunteers
- 280 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Vivax Malaria, G6PD Deficiency
Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.
A non randomized observation study that is aiming to assess the safety and efficacy of high dose primaquine (1mg/kg per day over 7 days) among patients with intermediate (30-70%) G6PD activity and the safety and efficacy of…
- Trial name
- NCT07468513
- Testing
- Patients with G6PD enzyme activities between 30 and <70% of the AMM will be treated with schizontocidal treatment plus high dose primaquine 1mg/kg/day for 7 days, Patients with G6PD enzyme activities <30% of the AMM will be treated with schizontocidal treatment plus 8 weekly primaquine (0.75mg/kg dose).
- Where
- 4 sites in Brazil, Ethiopia and 1 more
- Volunteers
- 100 people
- Sponsor
- Menzies School of Health Research
Pneumocystis, Pneumocystis Infection
Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)
The usual first treatment for Pneumocystis jirovecii pneumonia (PCP) is an antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX).
- Conditions
- Pneumocystis, Pneumocystis Infection, Pneumocystis Carinii Infection, Pneumocystis Carinii; Infection, Resulting From HIV Disease
- Trial name
- SPIRIT-ALT (NCT07357103)
- Testing
- Clindamycin + primaquine, Pentamidine, Atovaquone
- Volunteers
- 416 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Falciparum Malaria
Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda
The purpose of this study is to evaluate the safety and efficacy of lower doses of primaquine compared to the dose recommended by the WHO for reducing P.
- Trial name
- NCT01365598
- Testing
- Primaquine
- Where
- Uganda
- Volunteers
- 468 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Vivax Malaria, G6PD Deficiency
Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia
The proportion of malaria that is the Plasmodium vivax species is increasing in Indonesia. Reducing vivax malaria will require innovative solutions to cure both the blood and liver stages of the disease.
- Trial name
- SCOPE (NCT05879224)
- Testing
- Revised case management package
- Where
- 6 sites in Indonesia
- Volunteers
- 2,999 people
- Sponsor
- Menzies School of Health Research
Malaria
Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent
This is a single-centre, controlled, open label study using P. falciparum-induced blood stage malaria (IBSM) infection to assess the effectiveness of OZ439 as a gametocytocidal agent, as well as its treatment effects on…
- Trial name
- OZGAM (NCT02431650)
- Testing
- OZ439, Primaquine
- Where
- Australia
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria, Glucose 6 Phosphate Dehydrogenase Deficiency
Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen
To investigate the comparative tolerability, metabolism and pharmacokinetics of individual enantiomers of PQ in healthy human volunteers, receiving study drug over the course of 7 days.
- Trial name
- NCT03934450
- Testing
- RPQ, SPQ, Primaquine Phosphate
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Mississippi, Oxford
Uncomplicated Vivax Malaria
IMPROV (Improving the Radical Cure of Vivax Malaria)
The main determinant of primaquine efficacy is the total dose of primaquine administered, rather than the dosing schedule. Previous trials have demonstrated that the standard low dose regimen of primaquine (3.5 mg/kg total) fails…
- Trial name
- NCT01814683
- Testing
- Primaquine
- Where
- 8 sites in Afghanistan, Ethiopia and 2 more
- Volunteers
- 2,388 people
- Sponsor
- University of Oxford
Malaria Vivax
Efficacy of Chloroquine-Primaquine Treatment for Uncomplicated Plasmodium Vivax Malaria
The study was designed to evaluate the current efficacy of this combination therapy against P. vivax, given the possibility of misuse or inadequate adherence to the regimen due to its lengthy treatment duration, in one of a…
- Trial name
- CQ-PQ (NCT07753967)
- Testing
- CQ-PQ
- Where
- Ethiopia
- Volunteers
- 192 people
- Sponsor
- Jimma University
Malaria
Phase 2 Efficacy Study of Primaquine and Methylene Blue
The purpose of this study is to determine the most efficacious transmission blocking drug regimen for seasonal malaria chemoprophylaxis in Mali.
- Trial name
- NCT02831023
- Testing
- Sulphadoxine-pyrimethamine, 0.25 mg/kg primaquine, Dihydroartemisinin-piperaquine
- Where
- Mali
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Plasmodium Falciparum
Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes
The purpose of this study is to assess efficacy and safety of a single low-dose Primaquine added to standard artemether/lumefantrine treatment for the clearance of Plasmodium falciparum gametocytes among patients with…
- Trial name
- NCT02090036
- Testing
- Primaquine (For artemether-lumefantrine+primaquine arm)
- Where
- Tanzania
- Volunteers
- 220 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Malaria Transmission
The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy
The investigators' Hypothesis is that "The correct timing of gametocytocidal drug in combination with an effective Artemisinin Combination Therapy can limit the infectiousness of malaria-infected individuals to less than one week…
- Trial name
- NCT01906788
- Testing
- Artemether Lumefantrine, Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0, Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2
- Where
- Tanzania
- Volunteers
- 250 people
- Sponsor
- Kilimanjaro Clinical Research Institute
G6PD Normal, G6PD Deficient
Pharmacokinetic and in Vitro Transmission Blocking Activities Study of Primaquine Compare to Methylene Blue in Healthy Volunteer Both G6PD Normal and G6PD Deficiency
The emergence of partial artemisinin resistance in Plasmodium falciparum on the Cambodia-Thai border and more recently on the Myanmar-Thai border jeopardizes the renewed global efforts of control and elimination of malaria.
- Conditions
- G6PD Normal, G6PD Deficient, Healthy
- Trial name
- NCT01668433
- Testing
- Regimens (Primaquine, Methylene blue)
- Where
- Thailand
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Parasitemia
Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria
This research is intended to study the efficacy of CQ alone for P.vivax infection and also to study the recurrence rate among patients with P.vivax on standard dose of CQ and PQ.
- Trial name
- BCAPES (NCT01784315)
- Testing
- Artemisinin combination therapies (ACT)will be used for Chloroquine resistant P.vivax, Chloroquine and Primaquine
- Where
- 3 sites in Bhutan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ministry of Health, Bhutan
Vivax Malaria
Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan
This research is intended to study the efficacy of chloroquine (CQ) and primaquine (PQ) for Plasmodium vivax (P.vivax) infection, and also to study the recurrence rate among patients with P.vivax malaria on standard doses of CQ…
- Trial name
- NCT01716260
- Testing
- Chloroquine, Primaquine
- Where
- Bhutan
- Volunteers
- 24 people
- Sponsor
- Menzies School of Health Research
Malaria
Phase2a Primaquine Dose Escalation Study
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of low single-dose primaquine for gametocidal activity against P.falciparum among adult glucose-6-phosphate dehydrogenase (G6PD)-normal malaria…
- Trial name
- NCT01743820
- Testing
- dihydroartemisinin-piperaquine, 0.125 mg/kg Primaquine, 0.5 mg/kg Primaquine
- Where
- Mali
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco